Disease relevance of SIVA1

• Although Siva-1 expression is up-regulated in multiple pathological processes, little is known about the signaling pathway underlying the Siva-induced apoptosis [1].
• In this report we demonstrate that the human and murine proapoptotic protein Siva specifically interact with the CVB3 capsid protein VP2 [2].
• Analysis of Siva expressed in Escherichia coli revealed that this protein binds three zinc ions, suggesting a rather complex three-dimensional structure [3].

High impact information on SIVA1

• The Siva gene is organized into four exons that code for the predominant full-length Siva-1 transcript, whereas its alternate splice form, Siva-2, lacks exon 2 coding sequence [4].
• We identified novel p53-induced and DNA damage-induced genes (the proapoptotic SIVA gene and a set of transforming growth factor beta-related genes) [5].
• Through isolation and analysis of the SIVA promoter, we have identified response elements for both p53 and E2F1 [6].
• SIVA up-regulation is sufficient to initiate the apoptotic cascade in neurons [6].
• Siva-induced apoptosis is related to the CD27-mediated apoptotic pathway and results in activation of both initiator and effector caspases [1].

Biological context of SIVA1

• Here we report that CD70, a cytokine overexpressed in RCC, promotes lymphocyte apoptosis through interaction with its receptor CD27 and with the intracellular receptor-binding protein SIVA [7].
• The human Siva gene is localized to chromosome 14q32-33 and gives rise to the full-length predominant form, Siva-1 and a minor alternate form, Siva-2 that appears to lack the proapoptotic properties of Siva-1 [8].
• By screening a human heart cDNA library we found a new interaction partner of Siva [3].

Anatomical context of SIVA1

• In this study, we investigated the mechanism of the proapoptotic activity of Siva-1 and an alternative splice form lacking the death domain of Siva-1, Siva-2, in T lymphocytes in which Siva proteins, CD27, and glucocorticoid-induced TNFR family-related gene are primarily expressed [1].

Associations of SIVA1 with chemical compounds

• Overexpression of Siva proteins triggers a typical apoptotic process manifested by cell shrinkage and surface exposure of phosphatidylserine, and confirmed by ultrastructural features [1].
• These results indicate that at least three ionic currents-a TTX- and muO-conotoxin MrVIA-sensitive sodium current; a 4AP- and kappaA-conotoxin SIVA-sensitive potassium current; and a T- or R-type calcium current-contribute to the pacemaker rhythm [9].
• Today crossbow fatalities are extremely rare on both sides of the Atlantic but Dr Siva described a case of suicide in 1979 and Professor Gresham presented a case of crossbow homicide to the BAFM in June 1976 [10].
• Seeds of Dolichos lablab var. lignosus (field beans) and variety typicus (lablab beans) contain glucose/mannose specific lectins that have been affinity purified and well characterised (Siva Kumar N., and Rajagopal Rao, D., J.Biosci., 1986, 10, 95-109, (1) Rajasekhar et al., (Biochem.Archives [11].
• Seeds of Triticale (hybrid of wheat and rye) contain an N-acetylglucosamine specific lectin that was affinity purified in our laboratory (Siva Kumar, N. and Padma, K. (1996) "Affinity purification of N-acetyl glucosamine specific lectin. Purification and partial characterization of Triticale lectin". Biochem. Mol. Biol. Int. 38, 1059-1066) [12].

Analytical, diagnostic and therapeutic context of SIVA1

• Using DNA microarray analysis, we have found a striking induction of the proapoptotic gene, SIVA [6].
• Sequence analysis has shown that these consensus sites are also conserved between mouse and human SIVA genes [6].
• Electrophoretic mobility shift assays reveal that both transcription factors are capable of binding to putative consensus sites, and luciferase reporter assays reveal that E2F1 and p53 can activate transcription from the SIVA promoter [6].
• From SIVA to ISAP!--a logical evolution. Society for Intravenous Anesthesia. International Anesthesia Research Society [13].
• PURPOSE: The paper presents the main outline of a new research project carried out by the SIVA research team concerning the development of methodologies to select and use assistive technology to allow children with motor disabilities to play with toys [14].

References